Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Dana Winrow who wrote (939)	1/5/1998 8:48:00 PM
From: Sigmund	Read Replies (1) \| Respond to of 1894

Sounds a bit complacent to me. Pathfinder was purchased by NeoPath I assume not simply as a stand alone product but as a technology for further development to integrate with their AutoPap. The question then becomes what is there about the architecture of the two products which makes one or the other "ultimately" more functional or less costly? I have no opinion on this not being familiar with either product but I do know that to answer this question you can't just look at the current state of development of the two products. One also needs to compare the ACMI product to Pathfinder plus AutoPap as that is most likely the true market for their product. Perhaps NeoPath made a mistake by buying Pathfinder. I would not be in the least surprised by that. But to assume that two products which are today not comparable will in the future retain the same relationship is I think a bit complacent.